Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2016-09-30 Share Issue/Capital Cha…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the successful completion of a capital increase, raising €12.5 million through the issuance of new ordinary shares. This action directly relates to the company's financing activities and capital structure changes. Based on the provided definitions, the category 'Capital/Financing Update' (Code: CAP) is the most appropriate classification for an announcement detailing the raising of capital through share issuance.
2016-09-30 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the successful completion of a capital increase ('augmentation de capital') by Onxeo S.A., raising 12.5 M€. It details the number of new shares issued, the subscription price, the use of proceeds (funding R&D programs like Livatag, AsiDNA, and Beleodaq), and provides timelines for future clinical milestones. This activity directly relates to the company's fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), as it focuses purely on the financing event.
2016-09-30 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "Onxeo Launches Capital Increase" and details the intention to issue new ordinary shares without preferential subscription rights, reserved for specific investors. It discusses financing R&D programs and outlines the structure, pricing, and regulatory context (French Commercial Code, AMF) of the share issuance. This activity directly relates to changes in the company's capital structure and fundraising efforts. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-09-29 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "Onxeo lance une augmentation de capital" (Onxeo launches a capital increase). It details the launch of a new share issuance reserved for specific investors to raise capital to fund R&D programs (Livatag, AsiDNA, Beleodaq). This clearly falls under the category of financing activities and capital structure changes. The appropriate code is 'CAP' (Capital/Financing Update). The document is a full announcement, not just a notice that a report is attached, so RPA/RNS is not the primary classification.
2016-09-29 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated September 12, 2016, announcing preclinical study results for the drug Livatag®. It details scientific findings, quotes the Chief Scientific Officer, and provides company background and contact information. This format is characteristic of an initial announcement of scientific or operational news, rather than a comprehensive financial report (like 10-K or IR) or a formal regulatory filing like a proxy statement or dividend notice. Since it is an announcement of results/data, it fits best under 'Earnings Release' (ER) if it were quarterly results, but since it is specific scientific/pipeline data, it is most accurately classified as a general announcement that doesn't fit the other specific categories. However, given the options, this type of announcement, which is essentially a news release detailing operational/pipeline progress, often falls under the general 'Regulatory Filings' (RNS) category if it's not a formal financial report or a specific event announcement. Given the content is scientific data release, it is not an ER (which is usually financial results), nor an IP (which is a presentation). It is a press release announcing data, which often defaults to RNS if no better fit exists. Since it is not a formal report itself, RPA is unlikely. I will classify it as RNS as a general regulatory/press announcement.
2016-09-12 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo announcing preclinical results for its drug Livatag®. It details scientific findings, quotes the CSO, and provides company background and forward-looking statements. This type of announcement, which releases key periodic operational or scientific updates outside of a formal quarterly/annual report or a specific regulatory filing like a Director's Dealing or Dividend notice, most closely aligns with an Earnings Release (ER) if it were financial results, or a general Regulatory Filing (RNS) if it's scientific/operational news. Since it is a scientific update rather than a formal financial report (like 10-K or IR) or a specific transaction announcement, and it is a formal announcement of news, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/corporate announcement, or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a press release. Given the options, RNS is the most appropriate fallback for a significant, non-standard corporate announcement that isn't a financial report itself. However, because it is a detailed announcement of scientific progress, it often serves the function of an Investor Presentation (IP) or a specific scientific update. Given the context of financial reporting databases, press releases announcing scientific milestones are often categorized as RNS or sometimes IP if they contain substantial data presentation elements. Since this is a news announcement about research results, RNS is the safest general classification for non-standard corporate news.
2016-09-12 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.